七月 2026
iDEXIS Compounding热门域名的总访问量
了解iDEXIS Compounding市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
iDEXIS Compounding热门域名的平均访问时长
分析iDEXIS Compounding参与度指标。
过去 3 个月的平均访问时长
子公司明细
iDEXIS Compounding热门域名的平均页面浏览量
了解iDEXIS Compounding如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
iDEXIS Compounding 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Novo Nordisk A/S filed suit against Idexis on Jun 1st '26.The warning follows a High Court interim order granted last month barring iDexis from manufacturing and selling medicines containing semaglutide, in a case brought by Novo Nordisk.
七月 13, 2026阅读更多
新闻Idexis had issues with illegally manufacturing and selling unregistered semaglutide products and competing in South Africa's fast-growing weight-loss market without complying with medicines regulations on Jun 1st '26.The Danish drugmaker argued that iDexis was illegally manufacturing and selling unregistered semaglutide products and competing in South Africa's fast-growing weight-loss market without complying with medicines regulations.
七月 9, 2026阅读更多
新闻Idexis had issues with producing unauthorized copies of semaglutide on Jun 10th '26.Novo Nordisk has on Wednesday sued the South African pharmacy Idexis in court for producing unauthorized copies of semaglutide.
六月 10, 2026阅读更多
查看 iDEXIS Compounding 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
